Amanote Research
Register
Sign In
Euglycemic Diabetic Ketoacidosis Induced by Empagliflozin, Sodium-Glucose Cotransporter-2 Inhibitor, in Patient With Diabetes Mellitus Type 2 After Thoracic Surgery
Lijecnicki Vjesnik
- Croatia
doi 10.26800/lv-142-1-2-1
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Date
January 1, 2020
Authors
Unknown
Publisher
Croatian Medical Association
Related search
Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor Related Diabetic Ketoacidosis
European Scientific Journal ESJ
Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
Journal of Investigative Medicine High Impact Case Reports
Risk
Epidemiology
Reliability
Safety
Safety Research
Quality
Ertugliflozin: A Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor for Glycemic Control in Type 2 Diabetes
Therapeutics and Clinical Risk Management
A Case of Back Abscess and Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus
Diabetes Case Reports
Empagliflozin: A New Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Drugs in Context
Molecular Medicine
Pharmacology
Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Differential Cardiovascular Profiles of Sodium-Glucose Cotransporter 2 Inhibitors: Critical Evaluation of Empagliflozin
Therapeutics and Clinical Risk Management
Relationship Between Euglycemic Diabetic Ketoacidosis and SGLT-2 Inhibitors
Global Journal of Endocrinological Metabolism
The Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin Does Not Prolong QT Interval in a Thorough QT (TQT) Study
Cardiovascular Diabetology
Internal Medicine
Cardiology
Endocrinology
Cardiovascular Medicine
Metabolism
Diabetes
